DeepMed Research

NATIONAL INSTITUTES OF HEALTH

🇺🇸United States

Country: 🇺🇸United States

Ownership: Subsidiary, Private

Established: 1948-01-01

Employees: 1K

Market Cap: -

Website: http://www.nidcr.nih.gov

Clinical Trials

Phase I/II Study of Pacritinib, A JAK2/IRAK1/CSF1R Inhibitor, in Refractory Chronic Graft-Versus-Host Disease (cGVHD) After Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)

Phase 1

Recruiting

Conditions: Graft vs Host Disease

Interventions: Drug: Pacritinib

First Posted Date: 2022-09-08

Last Posted Date: 2025-05-09

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 50

Registration Number: NCT05531786

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Study to Determine Possible Effects of Apalutamide, Compared to Placebo, on EGFR Expression in Patients With Non-muscle Invasive Bladder Cancer

Phase 1

Not yet recruiting

Conditions: Non-Muscle Invasive Bladder Urothelial Carcinoma
Recurrent Non-Muscle Invasive Bladder Urothelial Carcinoma

Interventions: Drug: Apalutamide
Procedure: Biopsy Procedure
Procedure: Biospecimen Collection
Drug: Placebo Administration
Other: Questionnaire Administration
Procedure: Transurethral Resection of Bladder Tumor

First Posted Date: 2022-08-30

Last Posted Date: 2025-05-04

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 80

Registration Number: NCT05521698

Locations: 🇺🇸
University of Arizona Cancer Center - Prevention Research Clinic, Tucson, Arizona, United States
🇺🇸
University of Wisconsin Carbone Cancer Center - University Hospital, Madison, Wisconsin, United States
🇺🇸
Cedars Sinai Medical Center, Los Angeles, California, United States

and more 3 locations

Testing Copanlisib as a Potential Targeted Treatment in Cancers With PIK3CA Mutations (MATCH-Subprotocol Z1F)

Phase 2

Active, not recruiting

Conditions: Advanced Lymphoma
Advanced Malignant Solid Neoplasm
Hematopoietic and Lymphatic System Neoplasm
Refractory Lymphoma
Refractory Malignant Solid Neoplasm
Refractory Multiple Myeloma

Interventions: Procedure: Biopsy Procedure
Procedure: Computed Tomography
Drug: Copanlisib Hydrochloride
Procedure: Magnetic Resonance Imaging

First Posted Date: 2022-08-08

Last Posted Date: 2025-05-06

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 35

Registration Number: NCT05490771

Locations: 🇺🇸
ECOG-ACRIN Cancer Research Group, Philadelphia, Pennsylvania, United States

Study of Growth Hormone Inhibition Using Pegvisomant in Severe Insulin Resistance

Phase 2

Recruiting

Conditions: Partial Lipodystrophy
Insulin Receptor Mutation

Interventions: Drug: Pegvisomant

First Posted Date: 2022-07-22

Last Posted Date: 2025-04-18

Lead Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Target Recruit Count: 25

Registration Number: NCT05470504

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Trial of Allogeneic Reduced-Intensity, HLA-Haploidentical Allogeneic Hematopoietic Cell Bone Marrow Transplantation Followed by Graft-versus-Host-Disease (GVHD) Prophylaxis With Cyclophosphamide, Bortezomib and Maraviroc for Hematologic Malignancies ...

Phase 1

Recruiting

Conditions: HIV
Hematologic Malignancies

Interventions: Drug: RIC
Drug: GVHD prophylaxis
Procedure: allo HCT
Drug: Plerixafor
Drug: Maraviroc

First Posted Date: 2022-07-22

Last Posted Date: 2025-05-18

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 265

Registration Number: NCT05470491

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Feasibility and Preliminary Efficacy of Acceptance and Commitment Therapy (ACT) for Sleep Disturbances in Adults With Sickle Cell Disease (SCD)

Not Applicable

Recruiting

Conditions: Sickle Cell Anemia
Insomnia
Sleeplessness
Transient Insomnia
Sickle Cell Disease
Nonorganic Insomnia
Chronic Insomnia

Interventions: Behavioral: ACT Intervention
Behavioral: Waitlist

First Posted Date: 2022-07-14

Last Posted Date: 2025-04-16

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 36

Registration Number: NCT05457790

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

N-803 Alone or in Combination With BN-Brachyury Vaccine or Bintrafusp Alfa (M7824) for Participants With Castration Resistant Prostate Cancer

Phase 2

Withdrawn

Conditions: Castration Resistant Prostate Cancer

Interventions: Drug: Bintrafusp alfa
Drug: N-803
Biological: BN-Brachyury

First Posted Date: 2022-07-06

Last Posted Date: 2024-04-02

Lead Sponsor: National Cancer Institute (NCI)

Registration Number: NCT05445882

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

CD19/CD22 Bicistronic Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory CD19/CD22-expressing B Cell Malignancies

Phase 1

Recruiting

Conditions: B-Non Hodgkin Lymphoma
Leukemia, Lymphocytic, B Cell
B-Cell Leukemia
B-NHL
Acute Lymphocytic Leukemia
Acute Lymphoblastic Leukemia
B-precursor ALL
B-All
Lymphoma, Non-Hodgkin
B-Cell Lymphoma

Interventions: Biological: CD19/CD22-CAR-transduced T cells
Drug: cyclophosphamide
Drug: fludarabine

First Posted Date: 2022-07-05

Last Posted Date: 2025-05-21

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 126

Registration Number: NCT05442515

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

CAR-Multicenter Analysis (CAR-MA): Retrospective Study to Characterize CAR T-cell Outcomes and Related Toxicities in Children and Young Adults With B-ALL

Completed

Conditions: Leukemia, Acute Lymphoblastic
Lymphoblastic Leukemia, Acute, Childhood

First Posted Date: 2022-06-30

Last Posted Date: 2024-12-16

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 57

Registration Number: NCT05440409

Locations: 🇺🇸
National Cancer Institute (NCI), Bethesda, Maryland, United States

The Lowest Effective Dose of Post-Transplantation Cyclophosphamide in Combination With Sirolimus and Mycophenolate Mofetil as Graft-Versus-Host Disease Prophylaxis After Reduced Intensity Conditioning and Peripheral Blood Stem Cell Transplantation

Phase 1

Recruiting

Conditions: Peripheral Blood Stem Cell Transplantation
Hematopoietic Stem Cell Transplantation

Interventions: Drug: Melphalan
Drug: Sirolimus
Radiation: Total Body Irradiation (TBI)
Drug: Cyclophosphamide
Drug: Mycophenolate Mofeti
Drug: Fludarabine
Procedure: Allogeneic HSCT
Drug: Mesna
Drug: Filgrastim

First Posted Date: 2022-06-29

Last Posted Date: 2025-04-15

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 260

Registration Number: NCT05436418

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
🇺🇸
City of Hope, Duarte, California, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy